Cordis Corporation Introduces DURA STAR(TM) Rx PTCA Dilatation Catheter
Share:
BRUSSELS, April 10--- Launch in Line With Cordis' Commitment to Offer Full Range of Products for Catheterization Labs
Cordis Corporation today announced the launch of the DURA STAR(TM) Rx
Percutaneous Transluminal Coronary Angioplasty (PTCA) Dilatation Catheter. The new dilatation balloon from Cordis is now available in Europe and will be introduced in other regions, including North America, later in the year.
The DURA STAR(TM) Rx (Rapid Exchange) Dilatation Catheter facilitates the post-delivery expansion of stents in coronary arteries and is suitable for tackling tortuous anatomy and calcified lesions (blockages). It has been designed to provide interventional cardiologists with controlled and even expansion of the balloon to the correct diameter, minimizing the potential for artery damage to the patient.
"The DURA STAR(TM) Rx PTCA Catheter performed well under challenging circumstances," said Andreas Baumbach, M.D., F.R.C.P., F.E.S.C., of Bristol Royal Infirmary in the United Kingdom, who conducted some of the earliest cases with the balloon in Europe. "It is excellent for post-delivery dilatation of stents. It entered and exited the stent easily. It gave controlled and precise expansion to the correct diameter and did not distort at high pressure. In short, the DURA STAR(TM) Rx PTCA Catheter allowed for enhanced accuracy and speed during procedures, ultimately benefiting the patients."
The DURA STAR(TM) Rx PTCA Catheter is suited for use in both drug-eluting and bare-metal balloon-expandable stents. Its short and soft tip facilitates crossing stent struts and calcified lesions. Designed to reduce the risk of "kinking" (twisting back on itself) and equipped with a lubricating coating, the DURA STAR(TM) Rx PTCA Catheter provides easier delivery to the site of a lesion, especially in challenging cases. The balloon is available in various lengths from 10 to 30 mm and from 2.25 to 4.0 mm in diameter.
"The introduction of the DURA STAR(TM) Rx PTCA Catheter, following the recent addition of the REGATTA(TM) Steerable Guidewires to our family of products, is further indication of the commitment by Cordis to offer a comprehensive product portfolio to support interventional cardiologists and catheter lab teams," said Hans-Peter Stoll, M.D., Director of Clinical Research and Medical Affairs for Cordis in Europe, the Middle East and Africa (EMEA region).
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Source: Cordis Corporation
Contacts: Teresa Mueller, Office: +33-1-55-00-4433; Robert Mitchell, Office: +32-2-352-14-03, Mobile +44-0-7976-514833, Email: rmitche4@crdbe.jnj.com
